参考文献
[1]Fisher B，Jeong J H，Anderson S，et al.Twenty-five year follow-up of a randomized trial comparing radical mastec-tomy，total mastectomy，and total mastectomy followed by irradiation.NEngl J Med，2002，347：567.
[2]沈镇宙，陆劲松.乳腺癌临床研究新进展.中国癌症杂志，2001，11(5)，388.
[3]张保宁.乳腺癌外科100年.中华肿瘤杂志，2003，6：618.
[4]Degensberin G A.CeccarelliF.The history of breast canc-er surgery：early beginning to Halsted.Breast，1977，3：28.
[5]徐冰河.乳腺癌治疗研究新进展.肿瘤研究与临床，2004，16(2)：73.
[6]Fisher B，Anderson S Conservation surgery for the man-agement of invasive and noninvasive carcinoma of the breast：NSABP Trials.World J Surg，1994，18：63.
[7]吴在德.外科学.第5版.北京：人民卫生出版社，2000，357.
[8]Silveratein M J.Duetal carcinoma in situ of the breast.Br JSurg，1997，84：145.
[9]Fisher E R，Wang J，Bryant J，et al.Pathobiology of pre-operative chemotherapy：findings from the National Sur-gical A～uvant Breast and Bowel Protocol(NSABP)B-18.Cancer，2002，95(4)：681.
[10]Bui，Kimmie L，Lamb，et al.Accuracy of mammograph-ic and sonographic assessment of preoperative breast cancer.Size.Women's Imaging，2003，5(3)：128.
[11]Inaji H，Komoike Y，Motomura K，et al.Breast-con-serving treatment after neoadjuvant chemotherapy in large breast cancer.Breast Cancer，2002，9(1)：20.(https://www.daowen.com)
[12]李树玲.秋水仙碱制剂辅助手术综合治疗乳腺癌.中华肿瘤杂志，1979，1(3)：212.
[13]Baum M，Budzar A U，Cuzick J，et al.Anastrozole alone or in combination withtamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer：first results of the A'FAC randomized trial.Lancet，2002，359(9324)：2131.
[14]Coombes R C，Hall E，Gibson L I，et al.A randomized trial ofexrnestane after two to three years of tamoxifen thera-py in postmenopausal women with primary breast cane-er.NEngl J IVied，2004，350(11)：1081.
[15]谷铣之，殷蔚伯.肿瘤放射治疗学.北京：北京医科大学中国协和医科大学联合出版社，1993.807.
[16]Bartelink H，Horiot J C，Poortmans P，et al.Recurrence rates after treatment of breast cancer with standardra-diotherapy with or without additional radiation.N Engl J Meal，2001，345：1378.
[17]Overgard M，Harsen P S，Overgeard J，et al.Postopera-tive radiotherapy in highrisk premenopausal women with breat cancer who receive adjuvant therapy.N Engl J Med，1997，337：949.
[18]Slamon D J，Leyland Jones B，Shak S，et al.Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2.N Engl J ivied，2001，344(11)：783.
[19]Pegram M，Hsu S，Lewis G，et al.Inhibitory effects of combinations of HER-2/neu antibody and chemothera-peutic agents used for the treatment of human breast cancers.Oncogene，1999，18(13)：2241.
[20]Leyland Jones B.Integration of Herceptin into breast cancer treatment algorithms.Anti Cancer Drugs，2002，13(suppl)：100.
[21]姜军.乳腺癌的免疫治疗.中国实用外科杂志，2001，21(9)：52.
[22]Berois N，Varangot M，Aizen B，et al.Molecular detec-tion of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer，Comparison of CKl9，MUCl，and CEA using R'I、PCR Eur J of Cancer，2000，36(6)：717.